Prelude Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $461K | Buy |
+12,681
| New | +$461K | 0.04% | 464 |
|
|
2025
Q1 | – | Sell |
-5,822
| Closed | -$245K | – | 1334 |
|
|
2024
Q4 | $245K | Sell |
5,822
-4,838
| -45% | -$204K | 0.02% | 775 |
|
|
2024
Q3 | $592K | Buy |
10,660
+4,460
| +72% | +$248K | 0.04% | 494 |
|
|
2024
Q2 | $255K | Sell |
6,200
-15,188
| -71% | -$624K | 0.02% | 780 |
|
|
2024
Q1 | $999K | Buy |
21,388
+16,488
| +336% | +$770K | 0.05% | 363 |
|
|
2023
Q4 | $234K | Buy |
+4,900
| New | +$234K | 0.02% | 746 |
|
|
2023
Q3 | – | Sell |
-4,788
| Closed | -$221K | – | 1182 |
|
|
2023
Q2 | $221K | Buy |
+4,788
| New | +$221K | 0.01% | 691 |
|
|
2022
Q4 | – | Sell |
-6,119
| Closed | -$253K | – | 1428 |
|
|
2022
Q3 | $253K | Buy |
+6,119
| New | +$253K | 0.01% | 929 |
|
|
2022
Q1 | – | Sell |
-2,759
| Closed | -$232K | – | 1825 |
|
|
2021
Q4 | $232K | Buy |
+2,759
| New | +$232K | 0.01% | 1157 |
|
|
2021
Q3 | – | Sell |
-3,869
| Closed | -$369K | – | 1650 |
|
|
2021
Q2 | $369K | Buy |
3,869
+1,884
| +95% | +$180K | 0.01% | 893 |
|
|
2021
Q1 | $226K | Buy |
+1,985
| New | +$226K | 0.01% | 891 |
|
|
2020
Q4 | – | Sell |
-794
| Closed | -$65K | – | 1391 |
|
|
2020
Q3 | $65K | Sell |
794
-4,728
| -86% | -$387K | ﹤0.01% | 805 |
|
|
2020
Q2 | $432K | Buy |
+5,522
| New | +$432K | 0.02% | 308 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 1439 |
|
|
2019
Q2 | – | Sell |
-129
| Closed | -$9K | – | 1629 |
|
|
2019
Q1 | $9K | Buy |
+129
| New | +$9K | ﹤0.01% | 1093 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 1719 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 1695 |
|
|
2016
Q2 | – | Sell |
-2,993
| Closed | -$189K | – | 1636 |
|
|
2016
Q1 | $189K | Buy |
+2,993
| New | +$189K | 0.03% | 517 |
|